Andrew Blauvelt

Long-term efficacy and safety of ixekizumab - interview with Andrew Blauvelt

Andrew Blauvelt, MD, MBA - Addressing the Unmet Needs of Patients With Moderate to Severe Psoriasis: A Visual Exploration of Disease Pathogenesis and the Clinical Potential of Targeting the TYK2 Pathway as a Novel Nonbiologic Oral Therapeutic Option

Andrew Blauvelt, MD, MBA - Addressing the Unmet Needs of Patients With Moderate to Severe Psoriasis: A Visual Exploration of Disease Pathogenesis and the Clinical Potential of Targeting the TYK2 Pathway as a Novel Nonbiologic Oral Therapeutic Option

Andrew Blauvelt, MD, MBA - Addressing the Unmet Needs of Patients With Moderate to Severe Psoriasis: A Visual Exploration of Disease Pathogenesis and the Clinical Potential of Targeting the TYK2 Pathway as a Novel Nonbiologic Oral Therapeutic Option

Andrew Blauvelt, MD, MBA - Addressing the Unmet Needs of Patients With Moderate to Severe Psoriasis: A Visual Exploration of Disease Pathogenesis and the Clinical Potential of Targeting the TYK2 Pathway as a Novel Nonbiologic Oral Therapeutic Option

Andrew Blauvelt, MD, MBA - Addressing the Unmet Needs of Patients With Moderate to Severe Psoriasis: A Visual Exploration of Disease Pathogenesis and the Clinical Potential of Targeting the TYK2 Pathway as a Novel Nonbiologic Oral Therapeutic Option

Andrew Blauvelt, MD, MBA - Addressing the Unmet Needs of Patients With Moderate to Severe Psoriasis: A Visual Exploration of Disease Pathogenesis and the Clinical Potential of Targeting the TYK2 Pathway as a Novel Nonbiologic Oral Therapeutic Option

Andrew Blauvelt, MD, MBA - Addressing the Unmet Needs of Patients With Moderate to Severe Psoriasis: A Visual Exploration of Disease Pathogenesis and the Clinical Potential of Targeting the TYK2 Pathway as a Novel Nonbiologic Oral Therapeutic Option

Andrew Blauvelt, MD, MBA - Addressing the Unmet Needs of Patients With Moderate to Severe Psoriasis: A Visual Exploration of Disease Pathogenesis and the Clinical Potential of Targeting the TYK2 Pathway as a Novel Nonbiologic Oral Therapeutic Option

Imani Day and Andrew Blauvelt on Detroit’s Design Legacy